Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment? Irene VirgoliniThe Innsbruck Team Editorial Commentary 14 August 2015 Pages: 1949 - 1954
Feasibility and utility of re-treatment with 177Lu-DOTATATE in GEP-NENs relapsed after treatment with 90Y-DOTATOC Stefano SeveriMaddalena SansoviniGiovanni Paganelli Original Article 26 June 2015 Pages: 1955 - 1963
The efficacy of 177Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis Seong-Jang KimKyoungjune PakSamuel Chang Original Article 09 August 2015 Pages: 1964 - 1970
Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks A. PfestroffM. Lusteron behalf of the Radionuclide Therapy Committee of the European Association of Nuclear Medicine Editorial 16 September 2015 Pages: 1971 - 1975
Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer Levent KabasakalMohammad AbuQbeitahTurkay Toklu Original Article 31 July 2015 Pages: 1976 - 1983
Prognostic role of metabolic parameters of 18F-FDG PET-CT scan performed during radiation therapy in locally advanced head and neck squamous cell carcinoma Myo MinPeter LinAllan Fowler Original Article Open access 17 June 2015 Pages: 1984 - 1994
Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism Tatjana Traub-WeidingerDaniel PutzerIrene Johanna Virgolini Original Article 15 July 2015 Pages: 1995 - 2001
Long-term outcomes of 131Iodine mIBG therapy in metastatic gastrointestinal pancreatic neuroendocrine tumours: single administration predicts non-responders Nicola MulhollandRiddhika ChakravarttyGillian Vivian Original Article 05 July 2015 Pages: 2002 - 2012
FDG-PET/CT findings in systemic mastocytosis: a French multicentre study S. Djelbani-AhmedM. O. ChandesrisM. Soussan Original Article 05 July 2015 Pages: 2013 - 2020
18 F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases Chunjing YuDonghui PanXiaoyuan Chen Original Article 01 July 2015 Pages: 2021 - 2028
A pilot study imaging integrin αvβ3 with RGD PET/CT in suspected lung cancer patients Song GaoHonghu WuShuanghu Yuan Original Article 09 July 2015 Pages: 2029 - 2037
Gastric injury from 90Y to left hepatic lobe tumors adjacent to the stomach: fact or fiction? Vanessa L. GatesRyan HickeyRiad Salem Original Article 21 July 2015 Pages: 2038 - 2044
Difficulties in deciding whether to ablate patients with putatively “low–intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study Savvas FrangosIoannis P. IakovouEvanthia I. Giannoula Original Article 01 August 2015 Pages: 2045 - 2055
Clinical value of FDG-PET/CT in suspected paraneoplastic syndromes: a retrospective analysis of 137 patients Stine Bjørn KristensenSøren HessPoul Flemming Høilund-Carlsen Original Article 21 July 2015 Pages: 2056 - 2063
The use of SPECT/CT for anatomical mapping of lymphatic drainage in vulvar cancer: possible implications for the extent of inguinal lymph node dissection Angela CollarinoMaarten L. DonswijkRenato A. Valdés Olmos Original Article 30 July 2015 Pages: 2064 - 2071
Harmonizing FDG PET quantification while maintaining optimal lesion detection: prospective multicentre validation in 517 oncology patients Elske QuakPierre-Yves Le RouxNicolas Aide Original Article Open access 30 July 2015 Pages: 2072 - 2082
99mTc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials Tarik Z. BelhocineFrancis G. BlankenbergChristophe Van de Wiele Review Article 16 August 2015 Pages: 2083 - 2097
A case of Fahr’s disease examined by multi-modal imaging Ferdinando CalabriaGabriele CiccarielloOrazio Schillaci Image of the Month 13 August 2015 Pages: 2098 - 2099